Physician profile
David E Einspahr
NPI 1780634923
$349.94
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $14.33 · 2021: $25.85 · 2022: $23.80.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $113.66 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $40.50 | 2019 | |
| Gilead Sciences, INC. | $29.85 | 2019-2021 | |
| Karyopharm Therapeutics INC. | $23.80 | 2022 | |
| Pfizer INC. | $22.85 | 2019 | |
| Lilly USA, LLC | $17.86 | 2019 | |
| Incyte Corporation | $17.05 | 2019 | |
| Merck Sharp & Dohme LLC | $15.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.87 | 2019 | |
| Amgen INC. | $14.33 | 2020 | |
| Acrotech Biopharma INC. | $13.93 | 2021 | |
| Abbvie INC. | $13.10 | 2019 | |
| Janssen Biotech, INC. | $12.55 | 2019 |
4 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Einspahr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.